A YORK firm says its full-year revenues will be 52% higher in 2024 than last year.

In a trading update, Abingdon Health reported strong commercial progress across all divisions with unaudited revenues in the year to June 30 of £6.1m. Second-half revenues were notably strong – up 55% in first-half revenues, and up 27% on the second half of 2023.

The firm, which specialises in lateral flow tests, has launched three Boots own-brand tests, for vitamin D, iron and a saliva pregnancy test.

Its contract development and manufacturing (CDMO) division earned £5.5m of the overall total.

RECOMMENDED READING

Chief executive Chris Yates said: “We are pleased to report another year of growing revenue performance with FY 2024 revenues 52% ahead of FY 2023. We were particularly pleased to achieve positive cashflow in Q4 2024.“Our key focus is to build a focused, high quality, sustainable, profitable business and we are making great strides towards this.

“We believe with our lateral flow focus, our comprehensive CDMO service proposition and growing self-test distribution platform that we are well placed to deliver further revenue growth in FY 2025 and beyond.”